Paul Newton and Johanna Joyce both discussed the role of cellular communication in breast cancer metastasis

Paul Newton and Johanna Joyce both discussed the role of cellular communication in breast cancer metastasis. a workshop as an opportunity for leading researchers in their respective fields to present and discuss scientific research highlights relevant to the utilization of techniques and technologies for studying cell-to-cell marketing communications in cancer. Avenues of future development and the potential for clinical power were primary features of these discussions. The scientific presentations and extensive ensuing discussions resulted in the identification of a number of research opportunities, which are summarized in this report. == Introduction == Advanced technologies such as nanotechnologies and microfluidics platforms as well as conventional three-dimensional (3D) organotypic cultures have contributed to an increased understanding of cancer biology at the single-cell level and at the Maltotriose level of communication between cells. This in turn is leading to a greater appreciation from the implications of intratumoral heterogeneity and the role of tumor microenvironment and vasculature in cancer progression and metastasis. Both, the Breast Cancer Research Foundation (BCRF) and the National Rabbit Polyclonal to ECM1 Cancer Institute (NCI) support research in these areas. In collaboration with the Memorial Sloan Kettering Cancer Center (MSKCC), the BCRF and NCI convened a workshop titled Cell-to-Cell Communication in Cancer that was hosted by MSKCC on 1415 July 2014. The workshop consisted of plenary presentations from researchers working at the interface of biology and engineering interspersed with breakout sessions to discuss aspects of cancer biology for which cellular analyses can yield clinically relevant insights into tumor behavior. Breakout program discussions centered on intratumoral heterogeneity, single-cell measurements, and modeling complex tumor microenvironment interactions. Discussions were aimed at determining ways in which the characterization of single cells and cell-to-cell interactions could improve the understanding and the treatment of cancer. A number of themes emerged from the presentations and discussions, including the diversity of factors that contribute to malignancy, heterogeneity, and the evolution of progression-linked mutations; the importance of intercellular signaling in tumor progression and invasion; and the need to developin vitroandex vivomodels that capture these factors and can predict tumor response to intervention. This report highlights the presentations and findings made by participants in three key areasimproving cancer diagnosis and therapy using single-cell analyses; the effects of cell-to-cell communication within the tumor microenvironment on cancer progression and metastasis; and methods and models for recapitulating the tumor microenvironment. == Single-cell analyses == Recent technological advances have enabled the comprehensive genetic and proteomic analysis of single tumor cells, as well as the isolation and analysis of either intact circulating tumor cells (CTCs) or circulating DNA from the blood of cancer patients. 1These techniques have already demonstrated clinical utility, such as use of CTCs as prognostic markers intended for advanced prostate cancer. 2Workshop presentations centered on the ways in which these technologies have also enabled fundamental studies of cancer cell signaling pathways, Maltotriose 3genomic heterogeneity and evolution, 4, 5and physical characteristics. 6, 7Both presentations and discussions highlighted the potential for insights from these studies to spark discovery and development of new therapeutic strategies and associated diagnostics. Howard Scher discussed the use of CTC analysis to provide non-invasive patient monitoring, including the possibility of capturing the change into therapy resistant disease in prostate cancer by tracking androgen receptor status of CTCs. Scher sights CTC analysis as more effective at capturing the heterogeneity of cancer cells than traditional bulk analysis from the tumor, and therefore potentially more likely to discover drug resistance as it emerges. The evolution of disease and emergence of therapy-resistant phenotypes has important implications intended for cancer treatment, and Nicholas Navin presented his work revealing that, in at least some cancers, evolution occurs not gradually but rather by stepwise clonal expansions, with different mutational types (e. g., copy number rearrangements versus point mutations) having quite different natural histories. Wei Wei focused his talk on analyzing intracellular signaling pathways in single tumor cells and how integrated genomics and functional proteomics studies on single tumor cells reveal connections between genomic information and biological function. By analyzing protein networks associated with obtained drug resistance in glioblastoma multiforme, his team is developing strategies to predict and pre-empt resistance through the use of targeted combination therapies. Scott Manalis demonstrated the use of his suspended microchannel resonator device to measure the mass of single cells in real time and showed that growth measurements on genetically Maltotriose characterized single cells can uncover the.